The chronic lymphocytic leukemia therapeutics market is expected to grow at a compound annual growth rate of 7% from 2025 to ...

The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

A combination of lisocabtagene maraleucel (liso-cel, Breyanzi) plus ibrutinib (Imbruvica) demonstrated a trend for better ...

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...

Discover BeOne Medicines' robust Q2 2025 performance, with 42% revenue growth, market leadership in oncology, and raised 2025 guidance.

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic ...

AngioDynamics, Inc. announced enrollment of the first patient in the AMBITION BTK study of the Auryon atherectomy system.

Discover the latest advancements in multiple sclerosis (MS) treatment, including innovative therapies and strategies for ...

BAKU, Azerbaijan, August 7. Cooperation in the development of the Baku-Tbilisi-Kars (BTK) railway line was discussed during ...